NCT02733094View on ClinicalTrials.gov

Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

September 10, 2019

Study Completion Date

September 19, 2019

Conditions
Pyoderma Gangrenosum
Interventions
DRUG

Secukinumab

Trial Locations (1)

80802

Technical University of Munich, Munich

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Technical University of Munich

OTHER